Anuh Pharma Q3 FY26: Revenue ₹201.18 Cr, PAT ₹13.45 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹197Cr
- +23.1% YoY
- +5.9% QoQ
- Net profit
- ₹13Cr
- +30% YoY
- +62.5% QoQ
- Margin
- 10%
- +1 pp YoY
- +4 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Anuh Pharma Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.
From Anuh Pharma Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr)
- Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6)
- Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33)
- Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7).
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion efforts have supported increased revenues and stronger product mix (Page 6).
- The company emphasizes continuing capacity expansion and higher utilization to drive sustainable margin improvement in upcoming quarters (Page 7).
- Strategic expansion plan includes pursuing selective inorganic growth opportunities alongside disciplined capital expenditure to strengthen product portfolio and market presence (Page 7).
- A dedicated 10,000 sq. ft. in-house R&D facility with 16 scientists is operational for developing new products and processes to support future market penetration and product pipeline expansion (Page 32).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 197 | 160 | +23.1% | 186 | +5.9% |
| Operating profit (EBITDA) | 19 | 15 | +26.7% | 12 | +58.3% |
| Operating margin | 10% | 9% | +1 pp | 6% | +4 pp |
| Profit before tax | 18 | 13 | +38.5% | 10 | +80% |
| Net profit (PAT) | 13 | 10 | +30% | 8 | +62.5% |
| EPS (₹) | 1.34 | 1.03 | +30.1% | 0.76 | +76.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q3 FY26 results?
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
